Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tadalafil in Men With Benign Prostatic Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men 45 years of age or older with benign prostatic hyperplasia (BPH) also referred to as BPH-lower urinary tract symptoms (LUTS) on the disease diagnostic criteria at the start of study.~* Provide signed informed consent at the start of the study.~* Agree not to use any other approved or experimental pharmacologic BPH, overactive bladder (OAB), or erectile dysfunction (ED) treatments anytime during the study.~* Have not taken finasteride therapy for at least 3 months before study drug is dispensed and dutasteride therapy for at least 6 months before study drug is dispensed.~* Have not taken other BPH therapy (including herbal preparations), OAB therapy, ED therapy for at least 4 weeks prior to study drug is dispensed.~* Have LUTS with a total International Prostate Symptom Score (IPSS) greater than or equal to 13 when study drug is dispensed.~* Have reduced urine flow (measured by special toilet equipment).~* Demonstrate compliance with study drug administration requirements.~Exclusion Criteria:~* Treated with nitrates~* Have unstable angina or angina that requires treatment.~* Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention).~* Have very high or very low blood pressure.~* Have certain neurological conditions associated with bladder problems or injuries to brain or spinal cord within a specified time of starting this study.~* Have uncontrolled diabetes.~* Have prostate cancer, are being treated for cancer.~* Have prostate specific antigen (PSA) greater than 10 nanograms per milliliter (ng/mL) at the start of study.

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet with tamsulosin dose orally (po) once daily (QD) and placebo capsule with tadalafil dose po QD for 12 weeks
- Tadalafil 5 milligram (mg) (Type: EXPERIMENTAL): Tadalafil 5 mg tablet po QD and placebo capsule po QD for 12 weeks
- Tamsulosin 0.4 mg (Type: ACTIVE_COMPARATOR): Tamsulosin 0.4 mg capsule po QD and placebo tablet po QD for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).